Alzheimer's disease
Drug research and approvals for alzheimer's disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 622 studies of alzheimer's disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 151 drug trials for it since 2013, and the EU has 10 authorised medicines for it.
- Recruiting worldwide: 622
- Trials authorized in Canada: 151
- FDA orphan approvals: 0
- EU medicines: 10
Recruiting Now
Newest start dates first, of 622 recruiting on ClinicalTrials.gov ↗- Tau Pathology in the Brain After Hip or Knee Replacement SurgeryNCT07871487 · Not reported · Uppsala University Hospital · starts Apr 1, 2029
- PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)NCT07169630 · Phase 1 · National Institute of Mental Health (NIMH) · starts Nov 19, 2026
- Neuroplasticity Enhancement From Cognitive Training Reinforced by PsilocybinNCT07721467 · Phase 2 · National Institute on Aging (NIA) · starts Nov 19, 2026
- PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)NCT07099053 · Not reported · National Institute on Aging (NIA) · starts Nov 19, 2026
- Predicting Pre-dementiaNCT07516119 · Not reported · Prevention Research Consortium Corp. · starts Nov 15, 2026
- Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's DiseaseNCT07781657 · Phase 2 · Hoffmann-La Roche · starts Nov 10, 2026
- CMN LIFU for Enhanced Amyloid Reduction (CLEART Study)NCT07866768 · Not applicable · University of California, San Francisco · starts Nov 1, 2026
- The Gut - PRO StudyNCT07413744 · Phase 1 · University of Wisconsin, Madison · starts Nov 1, 2026
- Exploratory Study of Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Patients With Mild Alzheimer's Disease…NCT07863011 · Not applicable · ReadyCure Inc. · starts Oct 26, 2026
- Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective StudyNCT07923812 · Not reported · Fudan University · starts Oct 26, 2026
Trials Authorized in Canada
The 10 newest of 151; search them all in Canada trials| Nov 3, 2026 | A rollover study to evaluate the safety, tolerability, and efficacy of long-term trontinemab administration in participants with alzheimer's diseaseTRONTINEMAB (RO7126209) / LANTHEUS ([18F]MK-6240) | Roche | Pending |
| Sep 25, 2026 | A proof-of-mechanism, open-label, parallel group study with an open-label extension phase to assess the safety, tolerability, pharmacokinetics, and…E2511 / [11C] MK 6884 / [18F] FEOBV | Eisai | Pending |
| Aug 27, 2026 | A phase 2b, randomized, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of obicetrapib in participants with…OBICETRAPIB (TA-8995) | NEWAMSTERDAM PHARMA B.V. | Pending |
| Jul 21, 2026 | An open-label, dose escalation study to evaluate the safety, tolerability, and pharmacodynamics of vy1706 in participants with early alzheimer’s diseaseVY1706 / [18F]MK-6240 (ISOLOGIC) | Voyager Therapeutics, Inc. | Pending |
| Jun 25, 2026 | A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week sar448851 treatment followed by open-label…SAR448851 / [18F] MK-6240 | SANOFI-AVENTIS CANADA INC | Ongoing |
| Jun 25, 2026 | A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety study of trontinemab in cognitively unimpaired…TRONTINEMAB (RO7126209) / [18F]MK-6240 (LANTHEUS) / VIZAMYL | Roche | Ongoing |
| Apr 23, 2026 | A phase 1/2a placebo-controlled dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of aro-mapt-sc in healthy…ADS-028 / [18F]MK-6240 | ARROWHEAD PHARMACEUTICALS, INC. | Ongoing |
| Apr 16, 2026 | Evaluating treatment response in alzheimer's disease using [ 18fj flutemelamol petVIZAMYL | UNIVERSITY OF SASKATCHEWAN | Pending |
| Apr 7, 2026 | A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of karxt + karx-ec for the treatment of…XANOMELINE-TROSPIUM (BMS-986510) / XANOMELINE (BMS-986519) | Bristol-Myers Squibb | Pending |
| Dec 31, 2025 | Phase 2/3, double-blind, placebo-controlled study to evaluate the safety and efficacy of exv-802 and exv- 801 in the treatment of agitation in participants…DERAMCICLANE (EXV-801) / EXV-802 (DEXTROMETHORPHAN-DERAMCICLANE) | EXCIVA GMBH | Ongoing |
Medicines Authorised in the EU
Newest first| Sep 24, 2025 | Kisunladonanemab | Eli Lilly Nederland B.V. | EMA ↗ |
| Apr 15, 2025 | Leqembilecanemab | Eisai GmbH | EMA ↗ |
| Dec 3, 2013 | Memantine Accordmemantine · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Jun 12, 2013 | Memantine ratiopharmmemantine · generic | Ratiopharm GmbH | EMA ↗ |
| Apr 28, 2013 | Marixino (previously Maruxa)memantine · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Apr 22, 2013 | Nemdatinememantine · generic | Actavis Group PTC ehf | EMA ↗ |
| Apr 21, 2013 | Memantine Mylanmemantine · generic | Mylan Pharmaceuticals Limited | EMA ↗ |
| Nov 22, 2012 | Memantine Merzmemantine hydrochloride | Merz Pharmaceuticals GmbH | EMA ↗ |
| May 17, 2002 | Axuramemantine | Merz Pharmaceuticals GmbH | EMA ↗ |
| May 15, 2002 | Ebixamemantine | H. Lundbeck A/S | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA